Form 4: Cardio Diagnostics Director Receives Stock Options

Director Peter K. Fung acquired 3,205 stock options in Cardio Diagnostics Holdings, Inc. as part of a routine equity grant.

Summary

• Director Peter K. Fung was granted 3,205 stock options in Cardio Diagnostics Holdings, Inc. (CDIO).
• The options have an exercise price of $1.95 per share.
• The grant was issued on March 31, 2026, and expires on March 31, 2036.
• Following this transaction, the director's total beneficial ownership of derivative securities increased to 9,513.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Dilutive impact of new option grants on existing shareholders.

Risks

• Market price volatility affecting the value of the granted options.
• The options remain underwater or unexercisable if the stock price does not perform above the $1.95 strike price.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize leadership and align interests with shareholders in the biotechnology and diagnostics sector.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is consistent with standard practices for small-cap healthcare companies.
• The 10-year expiration term is standard for executive and director equity incentive plans.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new derivative securities.

Next Steps

• Director may exercise options at any time between March 31, 2026, and March 31, 2036.

Key Dates

Keywords

CDIO, Cardio Diagnostics, Form 4, Insider Trading, Stock Options, Director Compensation